Elicio Therapeutics (ELTX) Total Current Liabilities (2020 - 2026)

Elicio Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 36.66% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (down 36.66% YoY), and the FY2025 full-year result was $8.1 million, down 29.62% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $7.2 million, down from $8.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $11.5 million in Q4 2024, with the low at $2.0 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $8.3 million across 5 years, with a median of $8.1 million in 2025.
• Annual changes were most pronounced in 2023 — Total Current Liabilities slumped 80.44% — and 2024, when it jumped 193.01%.
• Elicio Therapeutics' Total Current Liabilities stood at $6.9 million in 2022, then surged by 42.04% to $9.8 million in 2023, then gained by 18.12% to $11.5 million in 2024, then fell by 29.62% to $8.1 million in 2025, then fell by 10.86% to $7.2 million in 2026.
• The last three Total Current Liabilities figures came in at $7.2 million (Q1 2026), $8.1 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.